Filing Details
- Accession Number:
- 0001415889-23-015458
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-22 19:00:20
- Reporting Period:
- 2023-11-20
- Accepted Time:
- 2023-11-22 19:00:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750284 | Olema Pharmaceuticals Inc. | OLMA | Pharmaceutical Preparations (2834) | 300409740 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1831216 | C. David Myles | C/O Olema Pharmaceuticals, Inc. 780 Brannan St San Francisco CA 94103 | Ch. Discov. & Non-Clin Dev Off | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-20 | 26,250 | $0.00 | 587,728 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-11-21 | 6,776 | $14.87 | 580,952 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-21 | 200 | $15.32 | 580,752 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-11-22 | 6,653 | $13.89 | 574,099 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 12,831 | Indirect | See Footnote |
| Common Stock | 154,846 | Indirect | See Footnote |
Footnotes
- On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vestingupon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified onNovember 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.
- Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.
- The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with thevesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent adiscretionary trade by the Reporting Person.
- The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
- The shares are held by Myles Properties Inc., of which the Reporting Person is President.
Billionaire Hedge Funds
